Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma

NCT ID: NCT06609941

Last Updated: 2024-09-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-18
• Study Completion Date: 2025-02-01

Brief Summary

Bronchial asthma is a widespread chronic condition charactrized by inflammation and narrowing of airways, leading to repeateted episodes of breathlessness, wheezing and labored breathing.Breathing exercises help to manage hyperventilation often seen in asthmatic patients. To handle respiratory complications asthmatics are advised to practise nasal breathing techniques in conjunction with their prescribed medications.

Detailed Description

Bronchial asthma is a very common chronic disease marked by inflammation and constriction of airways, resulting in recurrent episodes of breathlessness, wheezing and decrease work of breathing. Breathing exercises help to manage hyperventilation associated with asthma. In order to manage respiratory conditions asthmatic patients are encouraged for nasal breathing techniques along with pharmacological management. Hence the objective of the study is to compare the effects of alternative nostril breathing along with pharmacological management versus pharmacological management alone on dyspnea, control pause, asthma control and peak expiratory flow rate in patients with bronchial asthma.

Conditions

Bronchial Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nostril Breathing along with pharmacological therapy Group

Patients in this group will receive alternative nostril breathing along with pharmacological management.

Total 4 weeks protocol. Two sessions per week will be supervised by physiotherapist and 5 days at home. A home diary will be provided in order to ensure and follow-up that participants are performing breathing exercise at home.

Group Type: EXPERIMENTAL

Alternative nostril breathing

Intervention Type: OTHER

Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.

Pharmacological therapy

Intervention Type: DRUG

Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:

Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.

Week 01 and week 02:

Patients will receive medication prescribed by pulmonologist.

Week 03 and week 04:

Patients will receive medication prescribed by pulmonologist.

Pharmacological therapy Group

Patients will receive medication as prescribed by pulmonologist through stepwise approach according to symptoms and severity. Total 4 weeks protocol.

Before and after 4 weeks pre and post interventional values will be taken.

Group Type: ACTIVE_COMPARATOR

Pharmacological therapy

Intervention Type: DRUG

Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:

Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.

Week 01 and week 02:

Patients will receive medication prescribed by pulmonologist.

Week 03 and week 04:

Patients will receive medication prescribed by pulmonologist.

Interventions

Alternative nostril breathing

Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.

Intervention Type: OTHER

Pharmacological therapy

Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:

Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.

Week 01 and week 02:

Patients will receive medication prescribed by pulmonologist.

Week 03 and week 04:

Patients will receive medication prescribed by pulmonologist.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Adults: aged (18-45 years)
• Gender: Both males and females
• Grade1- Grade 4 on Modified MRC dyspnea scale
• Asthma severity classes (intermediate, mild persistent and moderate persistent asthma) acc. to NAEPP national asthma education and prevention program guidlin

Exclusion Criteria

• Patients having acute exacerbation of COPD or status asthmaticus
• Patients diagnosed with acute infections
• Patients unable to follow command/ instructions
• Asthma patients with >40 sec control pause duration
• Patients who fall in red zone of asthma action plan (PEFR < 50%)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Foundation University Islamabad

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Foundation University College of Physical Therapy

Rawalpindi, Punjab Province, Pakistan

Site Status: RECRUITING

Countries

Pakistan

Central Contacts

Bazkha Tariq Aslam Khawaja, DPT

Role: CONTACT

bazkhatariq@gmail.com

0333-1281293

Facility Contacts

Zara Khalid, DPT, MS-CPPT,PHD

Role: primary

zara.khalid@fui.edu.pk

0333-5415822

Other Identifiers

FUI/CTR/2024/25

Identifier Type: -

Identifier Source: org_study_id